APOE Genetics as a Major Determinant of Alzheimer’s Disease Pathobiology Workshop Day 2

This workshop will bring together investigators who have intensely investigated the effects of APOE on the brain, and the mechanism of Alzheimer’s disease (AD). During the two-day meeting participants will explore the best next steps to develop study approaches that will pinpoint the molecular, genetic, and epigenetic factors necessary for the successful identification of therapeutic approaches. Learn more: https://go.nia.nih.gov/3NMkmLi.

Session 4 | New technologies and moving towards therapeutics of APOE4
00:05:55 - Leveraging deep molecular profiling to understand APOE dependent and independent pathology, Carlos Cruchage, Ph.D., Washington University in St. Louis
00:28:15 - ApoeE2 and its role in plaque deposition, neuroinflammation, and neurodegeneration, Bradley (Brad) Hyman, M.D., Ph.D., Massachusetts General Hospital
00:42:00 - Clinical trial of APOE2 gene therapy, Ronald Crystal, M.D., Weill Cornell Medical College
1:12:56 - Potential therapeutic role for peripheral APOE, Guojun Bu, Ph.D., Hong Kong University of Science and Technology
1:32:15 - RNAi Modulation of ApoE: Delicate Balance between Plague Clearance and Glia Activation, Anastasia Khvorova, Ph.D., University of Massachusetts
1:55:00 - Combination therapy in NACC and ADNI Alzheimer’s participants: Impact of APOE genotype and Sex, Francesca Vitali, Ph.D., University of Arizona
2:12:30 - Using biomarkers in persons with different APOE variants to inform the study, treatment and prevention of AD, Eric Reiman, M.D., Banner Health
2:34:30 - Therapeutic Correction of ApoE4-Mediated Endolysosomal Dysfunction in Alzheimer's Disease, Joachim Herz, M.D., University of Texas Southwestern Medical Center
2:56:00 - Brainstorm Discussion

#APOE #Genetics #AlzheimersDisease